​

Veracyte (VCYT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VCYT Stock Forecast

Veracyte (VCYT) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $44.00, with a high of $44.00 and a low of $44.00. This represents a 39.55% increase from the last price of $31.53.

$15 $21 $27 $33 $39 $45 High: $44 Avg: $44 Low: $44 Last Closed Price: $31.53

VCYT Stock Rating

Veracyte stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (70.59%), 4 Hold (23.53%), 1 Sell (5.88%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 1 4 12 Strong Sell Sell Hold Buy Strong Buy

VCYT Price Target Upside V Benchmarks

TypeNameUpside
StockVeracyte39.55%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$35.00
Last Closing Price$31.53$31.53$31.53
Upside/Downside--11.01%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 252721-12
Mar, 252521-10
Feb, 252621-11
Jan, 252621-11
Dec, 243621-12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 07, 2024Mike MatsonNeedham$44.00$35.8522.73%39.55%
Aug 12, 2024Tejas SavantMorgan Stanley$26.00$29.41-11.59%-17.54%
May 04, 2022Morgan Stanley$23.00$21.009.52%-27.05%
May 04, 2022Needham$26.00$21.4621.16%-17.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2024UBSBuyinitialise
Oct 10, 2024GuggenheimBuyinitialise
Aug 12, 2024Morgan StanleyUnderweightUnderweighthold
Aug 07, 2024NeedhamBuyBuyhold
Jan 05, 2023ScotiabankSector Outperforminitialise

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-0.67$-1.11$-0.51$-1.02------
Avg Forecast$-0.61$-1.14$-0.61$-0.71$0.36$0.50$0.71$1.12$1.38$1.52
High Forecast$-0.61$-1.14$-0.61$-0.62$0.37$0.53$0.88$1.59$1.40$1.55
Low Forecast$-0.61$-1.14$-0.61$-0.77$0.35$0.48$0.54$0.65$1.35$1.49
Surprise %9.84%-2.63%-16.39%43.66%------

Revenue Forecast

$100M $220M $340M $460M $580M $700M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$117.48M$219.51M$296.54M$361.05M------
Avg Forecast$115.33M$214.82M$291.31M$354.58M$443.91M$487.76M$540.63M$592.77M$636.08M$672.40M
High Forecast$115.33M$214.82M$291.31M$354.58M$445.00M$490.33M$556.35M$592.84M$645.88M$682.76M
Low Forecast$115.33M$214.82M$291.31M$354.58M$442.63M$486.23M$531.04M$592.70M$626.12M$661.88M
Surprise %1.87%2.19%1.79%1.82%------

Net Income Forecast

$-250M $-170M $-90M $-10M $70M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-35.85M$-75.56M$-36.56M$-74.40M------
Avg Forecast$-27.31M$-170.25M$-59.07M$-74.40M$28.69M$40.22M$53.25M$73.70M$109.87M$121.46M
High Forecast$-21.84M$-136.20M$-47.26M$-59.52M$29.34M$42.10M$70.49M$126.78M$112.07M$123.89M
Low Forecast$-32.78M$-204.30M$-70.88M$-89.28M$28.03M$38.33M$42.91M$52.20M$107.63M$118.99M
Surprise %31.28%-55.62%-38.11%-------

VCYT Forecast FAQ

Is Veracyte stock a buy?

Veracyte stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Veracyte is a favorable investment for most analysts.

What is Veracyte's price target?

Veracyte's price target, set by 17 Wall Street analysts, averages $44 over the next 12 months. The price target range spans from $44 at the low end to $44 at the high end, suggesting a potential 39.55% change from the previous closing price of $31.53.

How does Veracyte stock forecast compare to its benchmarks?

Veracyte's stock forecast shows a 39.55% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Veracyte over the past three months?

  • April 2025: 16.67% Strong Buy, 58.33% Buy, 16.67% Hold, 8.33% Sell, 0% Strong Sell.
  • March 2025: 20.00% Strong Buy, 50.00% Buy, 20.00% Hold, 10.00% Sell, 0% Strong Sell.
  • February 2025: 18.18% Strong Buy, 54.55% Buy, 18.18% Hold, 9.09% Sell, 0% Strong Sell.

What is Veracyte’s EPS forecast?

Veracyte's average annual EPS forecast for its fiscal year ending in December 2024 is $0.36, marking a -135.29% decrease from the reported $-1.02 in 2023. Estimates for the following years are $0.5 in 2025, $0.71 in 2026, $1.12 in 2027, $1.38 in 2028, and $1.52 in 2029.

What is Veracyte’s revenue forecast?

Veracyte's average annual revenue forecast for its fiscal year ending in December 2024 is $443.91M, reflecting a 22.95% increase from the reported $361.05M in 2023. The forecast for 2025 is $487.76M, followed by $540.63M for 2026, $592.77M for 2027, $636.08M for 2028, and $672.4M for 2029.

What is Veracyte’s net income forecast?

Veracyte's net income forecast for the fiscal year ending in December 2024 stands at $28.69M, representing a -138.55% decrease from the reported $-74.404M in 2023. Projections indicate $40.22M in 2025, $53.25M in 2026, $73.7M in 2027, $109.87M in 2028, and $121.46M in 2029.